Premium
Inhibition of cyclooxygenase‐2 impairs the expression of essential plasma cell transcription factors and human B‐lymphocyte differentiation
Author(s) -
Bernard Matthew P.,
Phipps Richard P.
Publication year - 2010
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2009.03152.x
Subject(s) - antibody , immune system , cd38 , biology , cyclooxygenase , b cell , transcription factor , immunology , lymphocyte , microbiology and biotechnology , gene , enzyme , stem cell , biochemistry , cd34
Summary Cyclooxygenase (Cox) inhibitors are among the most widely used and commonly prescribed medications. Relatively little is understood about their influence on human immune responses. Herein, we discovered a novel and important mechanism whereby non‐steroidal anti‐inflammatory drugs (NSAIDs) blunt human B‐cell antibody production. We demonstrate that the Cox‐2 selective small molecule inhibitors SC‐58125 and NS‐398 attenuate the production of human antibody isotypes including immunoglobulin M (IgM), IgG1, IgG2, IgG3 and IgG4. In addition, inhibition of Cox‐2 significantly reduced the generation of CD38 + IgM + and CD38 + IgG + antibody‐secreting cells. Interestingly, we discovered that inhibition of Cox‐2 activity in normal human B cells severely reduced the messenger RNA and protein levels of the essential plasma cell transcription factor, Blimp‐1. These observations were mirrored in Cox‐2‐deficient mice, which had reduced CD138 + plasma cells and a near loss of Blimp‐1 expression. These new findings demonstrate a critical role for Cox‐2 in the terminal differentiation of human B lymphocytes to antibody‐secreting plasma cells. The use of NSAIDs may adversely influence the efficacy of vaccines, especially in the immunocompromised, elderly and when vaccines are weakly immunogenic.